| Literature DB >> 33223038 |
Cong Li1, Huijing Chen2, Qijia Tan1, Caijun Xie1, Wengang Zhan1, Aruna Sharma3, Hari Shanker Sharma4, Zhiqiang Zhang5.
Abstract
Glioma is the most common primary malignant brain tumor in adults and the patients have poor prognosis despite treatment with surgery, radiotherapy and chemotherapy. The anti-epileptic drug, valproic acid (VPA) as a HDAC inhibitors is often used in glioma patients even if the patients don't have brain tumors associated epilepsy (BAE). Some previous studies have found that VPA not only has anti-epileptic effect, but also has anti-glioma growth effect through enhance radiotherapy sensitivity or other mechanism. Then VPA is reported to improve the survival of glioma patients receiving chemoradiation therapy. In addition, there are limited researches have shown that VPA has a neuroprotective effect in protect normal cells and tissues from the deleterious effects of treatment of glioma, especially radiotherapy. We'll give a brief overview of these effects of VPA in glioma patients.Entities:
Keywords: Glioma; Neuroprotective effect; Valproic acid
Mesh:
Substances:
Year: 2020 PMID: 33223038 DOI: 10.1016/bs.pbr.2020.09.008
Source DB: PubMed Journal: Prog Brain Res ISSN: 0079-6123 Impact factor: 2.453